PEDIATRICS Vol. 44 No. 3 September 1969, pp. 418-428
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernandez, A.
Right arrow Articles by Goldring, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernandez, A.
Right arrow Articles by Goldring, D.

PHARMACODYNAMICS OF 3H-DIGOXIN IN INFANTS

Antonio Hernandez M.D.1, Robert M. Burton M.D.1, Reynaldo D. Pagtakhan M.D.1, and David Goldring M.D.1

1 Washington University School of Medicine, Mallinkrodt Department of Pediatrics, and Department of Pharmacology, Saint Louis

The absorption, tissue concentration, and urinary and fecal excretion of 3H-digoxin was studied in 20 infants with serious congenital cardiac malformations and, except for minor differences, the results were in the same range as those reported for adults.

The published recommendations of higher dosage requirements in infants for maximum therapeutic effectiveness and the suggested lower dosage for the neonatal period to reduce the danger of toxicity can therefore not be explained by differences in absorption, tissue fixation, and excretion of the glycoside by the neonate and infant when compared with the adult.

A major difference is that infants excrete primarily unchanged digoxin, whereas adults excrete both unaltered digoxin and metabolites.

Submitted on January 27, 1969
Accepted on March 31, 1969